Skip to main content
Sarepta Therapeutics, Inc. logo

Sarepta Therapeutics, Inc. — Investor Relations & Filings

Ticker · SRPT ISIN · US8036071004 LEI · 549300IKDPIED8J8IG21 US Manufacturing
Filings indexed 1,059 across all filing types
Latest filing 2025-05-15 Director's Dealing
Country US United States of America
Listing US SRPT

About Sarepta Therapeutics, Inc.

https://www.sarepta.com/

Sarepta Therapeutics is a commercial-stage biopharmaceutical company that engineers precision genetic medicines for rare diseases. The company's research and development efforts are centered on RNA-targeted therapeutics and gene therapies, with a primary focus on treating rare neuromuscular and central nervous system disorders. Sarepta aims to accelerate the drug development process from discovery to patient application and is building significant gene therapy manufacturing capabilities to support its mission.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2025-05-15 English
10-Q
Interim / Quarterly Report Q1 2025
2025-05-06 English
ARS
Annual Report
2025-04-24 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A filing, which is a proxy statement or related materials filed pursuant to Section 14(a) of the Securities Exchange Act of 1934. The text explicitly states it is a 'Definitive Additional Materials' filing related to a proxy statement. Proxy statements and related materials are classified under 'Proxy Solicitation & Information Statement' (PSI). The document length is short and it is not a full annual report or other financial report. Therefore, the correct classification is PSI.
2025-04-24 English
DEF 14A
Proxy Solicitation & Information Statement
2025-04-24 English
4
Director's Dealing
2025-03-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.